57

and IL-I produced a slgntficant mcrcasc in lung uptakeofradiolabeled

lymphocytes at 4 and 24 h, whcrcas IL-2 and IFN-gamma dccrcased

uptake at both time points. IL- I incrcascd uptake by liver al 4 and 24 h

while IL-2 mcrcascd uptake only at 4 h. WC conclude that the distribu- tlon or actlvatcd lymphocytes followmg adoptive tmnsfcr is altcred by

cylokincs. This findmg may have important rmplications for cell dclivcry dung adoptive immunotherapy.

Visualiration of bone pathologies and lung cancer with %Tc- glucose phosphate: A comparative study

Caner BE, Ercan MT, Bckdik CF, Varoglu E, Muczzinoglu S, Duman

Y ~1 al. Deparfmenl of Nuclear Medicine, Medical Faculty, llacerlepe

Universily. Ankara. Nuklcarmcduin 199 1;30: 132-6.

Glucose phosphate (GP) labcllcd with 99”‘Tc was used IO obtain

scintigraphic images of bone lesions in one group of patients (n = 28)

and of lung tumors in another (n = 35). All bone lesions detected by

P9”T~-MDP also demonsuatcd by P9”T~-GP; all lung tumors except 4

were dctcctcd by ‘vc-GP. the fatlure rate being about the same as that for6’Ga. The ~scof~~“Tc-GP isprcfcrablc t~thatof~~‘“Tc-MDP because

the fOrmcrdoesnotaccumulatc m normal bone; thcadvantag.~of~~“Tc-

GP over 67Ga hcs in its bcttcr physical charactcr&cs and the fact that the result or the study 1s available within a few hours rather than three days.

Small cell long cancer antigen expression difTers on ‘classic’ and

‘variant’ SCLC and carcinoid cells

Koros AMC. Atchison RW. Mitchell DL. Deparrmenl of lnfeclious D~seosesandMicrobiology, GraduateSchool offublic Health, Univer-

siry of Piusburgh, 130 DeSoro Sweel. fursburgh, PA 15261. Lung

Cancer 1991:7:225-34. The panel of 98 monoclonal anubodies (MOABS) (mouse or rat)

provided by the Second International Workshop on Small Cell Lung

Cancer Antigens was tested by Indirect immunolluorescence and flow

cytomeuy using prototype cell lines [NC]-H69 (SCLC ‘classic’), NCI-

N417 (SCLC ‘variam’), NCI-H727 (carcmoid) (A.F. Gazdar et al.,

Bethesda. MD)] as well as normal human peripheral blood lymphocytes

(PBL) and sea urchin coclomccytcs [Koros, A.M.C., Inl. J. Neurosci.

48: I61 (1989)J. Allcclls hadsomcrcactivitywthsomcofthcM0AB.S.

There ls, howcvcr. difCcrcnttaJ expression of anligens amongst the

prototype ccl1 hncs which may provide a us&l method forphenotypmg

human lung cancers.

Circulating heparin-like anticoagulant in a patient with small-cell lung carcinoma

Gamier G. Taillan B, Castancl J. Pcscc A. Dujardin P. Serwe de

Medecinelnrcmel, IlopiralDe Cuniez, BP 179.06003 Nice Cedex. Rev

Med lntcmc 1991;12:213-4.

Acqmrcd ctrculating heparin-like anticoagulants may have different

causes, the most frequent bcmg plasmocytc proltfcration. The authors

reporl an exceptional case of association between an heparin-like

Inhibitor and a small-cell anaplasttc lung carcinoma, and they revtew

the pathogcncsis, laboratory diagnostic methods and treatment of the

anticoagulant.

Initial staging of non-small cell lung cancer: Value of routine

radioisotope bone scanning Michel F, Solcr M. lmhof E, Pcrruchoud AP. Deparrmenl of Resprra-

lory Diseases. Universiry flospiral. C11403/ Bawl. Thorax 199 1;46:469- 73.

The excloslon of bone mctastascs IS important m the inmal staging of

non-small cell lung cancer, though there is dcbatc about whether bone

scans should be performed routmely or restricted to patients who

present with clintcal or laboratory indicators suggesting skeletal metas-

Lastx. In a prospcc~vc study ol’ I IO consecutive patients refcned for

inilial staging of non-small cell lung cancer, we assessed the sensitivity ofa group of clinical indicators (chest pain, skeletal pain, bone tender-

ness on physical cxammauon, swum alkaline phosphatase. and serum

calcmm) for the prcscncc of skclctal mctaslases as detcrmined by bone

scanning. The final staging rcstdt was validated with follow updataover at least three years. At the mitral staging 37 of 110 bone scans (34%)

showed arcas of incrcascd uptake, of which only nmc were confirmed

lo be mctastascs (by tomography, computed tomography, or biopsy).

Half the patlcnts (55) had at lcast one clinical indicator suggesting skclctal mctaslilscs, including all patients with proved skclctal mctasta-

scs. Thus the sensitivity of thcsc clmical mdicators was 100% and the

spcclficlty 54%. Within one year three of 27 patients with non-

confirmed posmvc bone scans had skclctal mctastascs, one of which

was m the arca that had shown incrcascd up&kc initially. All these

paticnls had clinrcal indicators [or skeletal mctastascs and all had

inoperable advanced turnours. Four al 69 patients wth an initially

negative bone scan dcvclopcd skclctal mctastascs within one year. It is

concluded that in non-small cell lung cancer bone scannmg can be

restrtctcd to paticnls with clinical indicators for skeletal metastases.

This approach rcduccs the number of bone scans and consccutivc

investigations without loss of scnsltivity in the dctcction of skeletal

mctastascs.

Immunochemical detection of a small cell lung cancer-associated

ganglioside (FucC(MI)) antigen in serum

VangstedAJ,Claoscn H,KjcldscnTB, WhiteT,Swecney B,Hakomori

S et al. Deparunenr of Tumor Cell Biology. The Fib&r Insrirule,

Dan&h Cancer Society. Ndr. Frlhavnsgade 70, DK-2100 Copenhagen.

Cancer Rcs 1991;51:2879-84.

Recently, the gangliostde FucG(Ml) Fuc_l-2Gal8l-3GalNAc8l 4[NeuAc_2-3]-Gal8l-4Glc8 I-1Cer)wasidcntificdasasmallcell lung

cancer (SCLC) marker both in chemical and histochemtcal studies. In order to further dctcrminc whcthcr the FucG(M1) gangliosidc IS shed

from the tumor site and conscqucntly is prcscnt in the serum of SCLC

patients, wc pmduccd a scrics of new monoclonal antibodies raised

against FucG(Ml) and rclatcd glycoliptds. Shedding of the FucG(Ml)

ganghosidc was stud& both in vitro and in vtvo using SCLC cell lmes

and nude mice xcnografts of SCLC cells as model systems, and finally

immunochemlcal analysts wcrc performed on scmm samples from

patients with SCLC. High-pcrformancc thin-layer chromatography

immunostaining dcmonsuatcd the prcscnce of FucG(Ml) in condi-

tioned culture media obtamcd from FucG(Ml)-posrtive SCLC cell

lines. Ftmhcrmorc, tumor extracts of SCLC cell line xenografts tn nude

mace were posttive for the FucG(M I ) marker, and more tmportantly the

marker was also prcscnt in swum samples from these mice. Twenty

serum samples wcrc obtained cram pattcnts with histologically vcnfied

SCLC. Eight patients had locali& discasc, and the remaining pattents had disscminatcd cancer involving mctastascs to other organ sites. Sera

from 4 of thcsc patients wcrc clearly positive, and 2 addittonal cases were found to be weakly positive. The positive patient sera were all

from patients with cxtcnsivc disease. Scra from I2 patients with non-

SCLC and 20 healthy mdivtduals wcrc all found to be negative. These

results clearly establish the FucG(M1) glycolipid as a potenual serum

marker of SCLC for which a sensttivc immunoassay should be devel-

oped and tested using a larger scrics of Serum samples.

Necrotizing bronchial aspergillosis in a patient receiving neoad-

juvant chemotherapy for non-small cell lung carcinoma

Niimi T, Kajita M, Saito H. Deparrmenr ojThoracic Surgery. Norio&

Chubu Hospital. 36-3 Gengo. Morioka-cho. Ohbu. Alchi 474. Chest 1991;100:277-9.

We describe a case of nccroti/.ing bronchlal aspergillosrs which

developed alter lobcctomy following ncoadjuvam chemotherapy in a 73-year-old woman with non-small cell lung cancer. The lesion was

visualized and biopsicd through FBS. which played a useful role for

early diagnosis of lhis disease. luacona/ole therapy was effective and safe.

Technetium-99m monoclonal antibody fragment (FAb) scintigra-

phy in the evaluation ofsmall cell lung cancer: A preliminary report

Morris IF, Krishnamurthy S, Antonovic R, Duncan C, Turner FE, Krishnamunhy GT. Nuclear Medicme Serwce (l/S). VA Medical

Cenrer, Ponland. OR 97207. Nucl Med Biol Int J Radtat Appl lnstmm

PartB 1991;18:613-20. Small cell lung cancer (SCC) has the most rapid growth rate of the

fourccll types and mcwtawcE early. Prcscnt imaging modalmcs for